A novel live attenuated duck Tembusu virus vaccine targeting N7 methyltransferase protects ducklings against pathogenic strains
Xuedong Wu,Shanzhi Huang,Mingshu Wang,Shun Chen,Mafeng Liu,Dekang Zhu,Xinxin Zhao,Ying Wu,Qiao Yang,Shaqiu Zhang,Juan Huang,Xumin Ou,Ling Zhang,Yunya Liu,Yanling Yu,Qun Gao,Sai Mao,Di Sun,Bin Tian,Zhongqiong Yin,Bo Jing,Anchun Cheng,Renyong Jia
DOI: https://doi.org/10.1186/s13567-023-01170-0
2023-06-15
Veterinary Research - Springer Nature
Abstract:Duck Tembusu virus (DTMUV), an emerging pathogenic flavivirus, causes markedly decreased egg production in laying duck and neurological dysfunction and death in ducklings. Vaccination is currently the most effective means for prevention and control of DTMUV. In previous study, we have found that methyltransferase (MTase) defective DTMUV is attenuated and induces a higher innate immunity. However, it is not clear whether MTase-deficient DTMUV can be used as a live attenuated vaccine (LAV). In this study, we investigated the immunogenicity and immunoprotection of N7-MTase defective recombinant DTMUV K61A, K182A and E218A in ducklings. These three mutants were highly attenuated in both virulence and proliferation in ducklings but still immunogenic. Furthermore, a single-dose immunization with K61A, K182A or E218A could induce robust T cell responses and humoral immune responses, which could protect ducks from the challenge of a lethal-dose of DTMUV-CQW1. Together, this study provides an ideal strategy to design LAVs for DTMUV by targeting N7-MTase without changing the antigen composition. This attenuated strategy targeting N7-MTase may apply to other flaviviruses.